[Pharmacokinetics and absolute bioavailability of bromopride from various pharmaceutical formulations]

Pharmacokinetics and absolute bioavailability of 4-amino-5-bromo-N-[2-(diethylamino)ethyl]-2-methoxybenzamide (bromopride, Viaben), in various preparations (bromopride injection solution, bromopride suppositories for adults, drops and capsules, respectively) in various dosages were calculated. Several investigations were performed: Study I: Absolute bioavailability of bromopride suppositories for adults (cross-over). Study 2: Pharmacokinetics of Bromopride drops after single dose of 15 and 30 mg bromopride as well as after multiple dose of 15 mg bromopride (Confarma). Study 3: Pharmacokinetics of bromopride capsules (Confarma). The chemical analysis was made for all studies with a nearly identical HPLC-method so that the results of the various studies were comparable. The studies led to the following result: The bioavailability of the substance bromopride amounts to about 70% and increases after multiple administration to about 90%. Statistically there is no difference between the bioavailabilities of the individual formulations.